Vericel [VCEL] vs Capricor [CAPR] Detailed Stock Comparison

Vericel Corporation

NASDAQ
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Vericel Corporation wins in 12 metrics, Capricor Therapeutics Inc. wins in 4 metrics, with 0 ties. Vericel Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Vericel Corporation Capricor Therapeutics Inc. Better
P/E Ratio (TTM) 106.36 -15.61 Vericel Corporation
Price-to-Book Ratio 4.86 6.62 Vericel Corporation
Debt-to-Equity Ratio 27.32 4.75 Capricor Therapeutics Inc.
PEG Ratio 7.09 -0.05 Vericel Corporation
EV/EBITDA 73.87 -16.23 Vericel Corporation
Profit Margin (TTM) 5.98% 0.00% Vericel Corporation
Operating Margin (TTM) 24.12% 0.00% Vericel Corporation
EBITDA Margin (TTM) 24.12% N/A N/A
Return on Equity 5.11% -46.56% Vericel Corporation
Return on Assets (TTM) 1.50% -25.68% Vericel Corporation
Free Cash Flow (TTM) $24.75M $-81.54M Vericel Corporation
1-Year Return -19.30% 202.93% Capricor Therapeutics Inc.
Price-to-Sales Ratio (TTM) 6.27 N/A N/A
Enterprise Value $1.67B $1.72B Capricor Therapeutics Inc.
EV/Revenue Ratio 6.04 N/A N/A
Gross Profit Margin (TTM) 78.70% N/A N/A
Revenue per Share (TTM) $5 $0 Vericel Corporation
Earnings per Share (Diluted) $0.32 $-2.26 Vericel Corporation
Beta (Stock Volatility) 1.21 0.48 Capricor Therapeutics Inc.
Short % of Float 13.64% 19.17% Vericel Corporation

Vericel Corporation vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

VCEL
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Vericel Corporation0.81%-1.49%-5.59%-2.57%-8.50%-3.26%
Capricor Therapeutics Inc.1.21%-6.88%-18.39%1.79%329.87%-3.43%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Vericel Corporation-19.30%1.21%-40.16%1,129.89%-45.72%-84.22%
Capricor Therapeutics Inc.202.93%558.46%676.17%-7.24%-90.64%-97.72%

Performance & Financial Health Analysis: Vericel Corporation vs Capricor Therapeutics Inc.

MetricVCELCAPR
Market Information
Market Cap i$1.75B$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i410,843987,380
90 Day Avg. Volume i683,1141,234,213
Last Close$34.73$27.67
52 Week Range$28.95 - $45.97$4.30 - $40.37
% from 52W High-24.45%-31.46%
All-Time High$1,590.00 (Sep 22, 1997)$3,500.00 (Oct 22, 2007)
% from All-Time High-97.82%-99.21%
Growth Metrics
Quarterly Revenue Growth0.23%N/A
Quarterly Earnings Growth0.17%-1.00%
Financial Health
Profit Margin (TTM) i0.06%0.00%
Operating Margin (TTM) i0.24%0.00%
Return on Equity (TTM) i0.05%-0.47%
Debt to Equity (MRQ) i27.324.75
Cash & Liquidity
Book Value per Share (MRQ)$7.01$5.33
Cash per Share (MRQ)$2.71$5.53
Operating Cash Flow (TTM) i$51.91M$-69,811,264
Levered Free Cash Flow (TTM) i$16.05M$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Vericel Corporation vs Capricor Therapeutics Inc.

MetricVCEL (Apr 24, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i106.36-15.61
Forward P/E i42.28-56.73
PEG Ratio i7.09-0.05
Price to Sales (TTM) i6.27N/A
Price to Book (MRQ) i4.866.62
Market Capitalization
Market Capitalization i$1.75B$2.04B
Enterprise Value i$1.67B$1.72B
Enterprise Value Metrics
Enterprise to Revenue i6.04N/A
Enterprise to EBITDA i73.87-16.23
Risk & Other Metrics
Beta i1.210.48
Book Value per Share (MRQ) i$7.01$5.33

Financial Statements Comparison: Vericel Corporation vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricVCEL (2025)CAPR (2025)
Revenue/Sales i276.26M0
Cost of Goods Sold i70.66MN/A
COGS % of Revenue i25.6%-
Gross Profit i205.60MN/A
Gross Margin i74.4%-
Research & Development i27.56M84.45M
Operating Income (EBIT) i11.04M-108.14M
Operating Margin i4.0%-
EBITDA i29.55M-106.21M
EBITDA Margin i10.7%-
Pre-Tax Income i17.38M-105.04M
Pre-Tax Income % of Revenue i6.3%-
Income Tax i859,0001,600
Income Tax % of Revenue i0.3%-
Net Income (Profit) i16.52M-105.04M
Profit Margin i6.0%-

Balance Sheet & Liquidity Metrics

MetricVCEL (2025)CAPR (2025)
Cash & Equivalents i100.09M287.85M
Total Current Assets i247.44M322.94M
Total Current Assets % of Revenue i89.6%-
Total Current Liabilities i49.15M35.84M
Total Current Liabilities % of Revenue i17.8%-
Long-Term Debt i82.28M14.32M
Long-Term Debt % of Revenue i29.8%-
Total Shareholders Equity i354.64M305.79M
Retained Earnings i-376.30M-304.88M
Retained Earnings % of Revenue i-136.2%-
Property, Plant & Equipment i64.77M22.27M

Cash Flow Statement Comparison

MetricVCEL (2025)CAPR (2025)
Operating Cash Flow i48.88M-71.86M
Operating Cash Flow % of Revenue i17.7%-
Capital Expenditures iN/A-11.72M
Free Cash Flow i24.75M-81.54M
FCF Margin i9.0%-
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricVCELCAPR
Shares Short i5.38M10.04M
Short Ratio i7.617.73
Short % of Float i13.64%19.17%
Shares Outstanding i50.62M57.37M
Float Shares i47.58M48.61M
% Held by Insiders i1.47%9.47%
% Held by Institutions i110.80%53.91%
% Held by Public i-12.27%36.62%

Dividend Analysis & Yield Comparison: Vericel Corporation vs Capricor Therapeutics Inc.

MetricVCELCAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A